💡 Exosomes are “cell-to-cell messengers” that can target specific cells and alter their behavior.
🔬 ExoXpert cultures cells, filters the exosomes, and can use them directly or load them with specific molecules.
🎯 The goal is to automate the production of exosomes using AI and real-time monitoring.
Introduction:
Exo Biologics, a contract development and manufacturing organization (CDMO) in Belgium, has launched ExoXpert, a service that provides exosomes to accelerate the development of therapies. Exosomes are extracellular vesicles that act as cell-to-cell messengers and can contain various molecules. ExoXpert cultures cells in a bioreactor to amplify them and produce nano-sized exosomes, which are then filtered and purified. These exosomes can be used as therapy as is, or loaded with specific molecules to target disease pathways. The goal is to achieve fully-automated production of exosomes in order to maintain consistency and scalability.
- Exo Biologics has launched ExoXpert, a service that provides exosomes to accelerate the development of therapies.
- ExoXpert cultures cells in a bioreactor to amplify them and produce nano-sized exosomes.
- The purified exosomes can be used as therapy as is, or loaded with specific molecules to target disease pathways.
- The key future goal for ExoXpert is fully-automated production of exosomes to maintain consistency and scalability.
Conclusion:
Exo Biologics’ ExoXpert service offers a promising approach to utilizing exosomes for therapeutic purposes. The ability to culture cells and produce exosomes at scale opens up new possibilities for treating a wide range of indications. The goal of achieving fully-automated production of exosomes highlights the importance of consistency and scalability in the field of exosome-based therapies. Further advancements in automation and the use of AI and software can help optimize the production process and make exosome therapies more accessible and efficient in the future.
